Jim Wassil - 04 Sep 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: EVP, Chief Scientific Ofc, COO
Issuer ticker: PCVX
Reported as of: 04 Sep 2026
Net transaction value: -$163,863
SEC form: 4
Accepted by SEC: 09 Sep 2026, 17:46:35 UTC
Prior SEC filing: 02 Sep 2026
Source filing: View source filing
Reporting owner signature: Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact

Key filing fact

Jim Wassil filed Form 4 for Vaxcyte, Inc. (PCVX) on 09 Sep 2026.

Key facts

This page summarizes Jim Wassil's Form 4 filing for Vaxcyte, Inc. (PCVX).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 09 Sep 2026, 17:46.

Change

Previous filing in this sequence was filed on 02 Sep 2026.
Current net transaction value: -$163,863.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001813798 Primary reporting owner

Wassil Jim

Relationship: EVP, Chief Scientific Ofc, COO
Address: C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS
Signature: Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact
Signature date: 09 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCVX transaction

Common Stock

Sale

Transaction value: $84,462
Shares: -1,381
Change %: -0.9%
Price: $61.16
Shares after: 152,228
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F1, F2

PCVX transaction

Common Stock

Tax liability

Transaction value
Shares: -5,459
Change %: -3.6%
Price: $60.36^*
Shares after: 146,769
Date: 08 Sep 2026
Ownership: Direct
Footnotes: F3

PCVX transaction

Common Stock

Sale

Transaction value: $79,401
Shares: -1,334
Change %: -0.91%
Price: $59.52
Shares after: 145,435
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

Footnote F2

The price reported is a weighted-average price. The shares were sold at prices ranging from $60.95 to $61.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Footnote F4

The price reported is a weighted-average price. The shares were sold at prices ranging from $59.155 to $60.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.